![[Insert title of meeting/event here]](https://www.docslides.com/dplay.png)
![[Insert title of meeting/event here]](https://thumbs.docslides.com/935541/insert-title-of-meeting-event-here-l.jpg)
Chapter 17 Respiratory conditions 1 Insert name of presenterunit here Insert date of presentation here 2 EVIDENCE Please access the National Essential Medicines List Committee NEMLC report for detailed evidence including rationale references and costings informing decisionm ID: 935541
Download Presentation The PPT/PDF document "[Insert title of meeting/event here]" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
![[Insert Event Title]](https://thumbs.docslides.com/570873/insert-event-title.jpg)
Slide1
[Insert title of meeting/event here]
Chapter 17: Respiratory conditions
1
[Insert name of presenter/unit here]
[Insert date of presentation here]
Slide22
EVIDENCE
Please access the National Essential Medicines List Committee (NEMLC) report for detailed evidence (including rationale, references and costings) informing decision-making on medicine addition, amendments and deletions:
http://www.health.gov.za/index.php/standard-treatment-guidelines-and-essential-medicines-list/category/285-phc
DISCLAIMER
This slide set is an implementation tool and should be used alongside the most recently published STG available on the EML Clinical Guide Application. This information does not supersede or replace the STG itself.
Slide33
Chronic asthma and COPD
DESCRIPTION
A chronic inflammatory disorder with reversible airways obstruction
CHANGES
Budesonide
ADDED
and
Beclomethasone
REMOVED
Budesonide
contra-indicated in patients on PIs – these patients should be referred for beclomethasone.
REASON
Budesonide is as effective
as and cheaper than
beclomethasone
Protease
inhibitors increase
blood
concentrations of
budesonide & fluticasone - could
lead to Cushing’s
syndrome
Slide44
COPD
DESCRIPTION
Chronic bronchitis and emphysema which are characterised by chronic cough ± sputum, dyspnoea or shortness of breath and wheezing
CHANGES
Patients
not controlled on salbutamol,
but
<
2
exacerbations per
year and COPD confirmed by spirometry:
Formoterol
(LABA without ICS)
ADDED
All other COPD patients not controlled on salbutamol alone: LABA+ICS combination inhaler
RETAINED
REASON
In asthma the
risks
of LABA alone without ICS is associated with increased mortality.
LABA alone must not be used unless the diagnosis of COPD has been confirmed by spirometry.
Slide55
Acute bronchitis
DESCRIPTION
Acute airways infections, mostly of viral origin, accompanied by cough and sputum production, in patients with otherwise healthy lungs
CHANGES
Antibiotic
treatment
REMOVED
REASON
A
ntibiotics do not improve cure rates, even in HIV-infected patients
Slide66
Pneumonia in children
DESCRIPTION
Acute infection of the lung parenchyma, usually caused by bacteria
CHANGES
Amoxicillin dose
AMENDED
from
8 hourly to 12
hourly
REASON
12 hourly dosing is as effective as 8 hourly dosing in children with pneumonia
Slide7THANK YOU